Details of the Drug

General Information of Drug (ID: DMSTHG1)

Drug Name

VX-371

Indication

Disease Entry	ICD 11	Status	REF
Cystic fibrosis	CA25	Phase 2	[1]
Primary ciliary dyskinesia	LA75.Y	Phase 2	[2]
------------------------------------------------------------------------------------

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amiloride-sensitive sodium channel (ENaC)	TTQM7TE	SCNNA_HUMAN ; SCNNB_HUMAN ; SCNNG_HUMAN ; SCNND_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02709109) A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT02871778) Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia (CLEAN-PCD). U.S. National Institutes of Health.
3	The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652.